A Phase IIb, Randomised, Double-blind, Placebo-controlled, Dose-range Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease

Trial Profile

A Phase IIb, Randomised, Double-blind, Placebo-controlled, Dose-range Investigation of the Safety and Efficacy of NTCELL® [Immunoprotected (Alginate-Encapsulated) Porcine Choroid Plexus Cells for Xenotransplantation] in Patients With Parkinson's Disease

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2017

At a glance

  • Drugs Choroid plexus cell replacement therapy (Primary)
  • Indications Parkinson's disease
  • Focus Adverse reactions; Registrational
  • Sponsors Living Cell Technologies
  • Most Recent Events

    • 21 Dec 2017 The 26 week results of this trial require further analysis and patients will continue to be monitored in accordance with the study extension protocol, as reported in a Living Cell Technologies media release.
    • 21 Dec 2017 One year follow up data in patients from all three groups of this study will be announced in May 2018, according to a Living Cell Technologies media release. The Board has decided to continue follow-up of this trial until May 2019.
    • 21 Dec 2017 26-week results of this trial were reported in November 2017, according to a Living Cell Technologies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top